iBio, Inc. Files 8-K: Material Agreement, Equity Sales

Ticker: IBIO · Form: 8-K · Filed: 2025-01-13T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, filing

TL;DR

iBio signed a big deal & sold stock, filing shows.

AI Summary

On January 10, 2025, iBio, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and other events. This filing was made on January 13, 2025.

Why It Matters

This filing indicates significant corporate activity for iBio, Inc., including the execution of a material agreement and potential equity transactions, which could impact its financial standing and strategic direction.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities and a material definitive agreement, which can introduce financial and operational risks if not managed properly.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by iBio, Inc. on January 10, 2025?

The specific details of the Material Definitive Agreement are not disclosed in this 8-K filing, which only reports its execution.

What type of equity securities were sold by iBio, Inc. under the unregistered sales?

This filing does not specify the type of equity securities involved in the unregistered sales.

What are the principal executive offices of iBio, Inc.?

The principal executive offices of iBio, Inc. are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

When was iBio, Inc. incorporated?

iBio, Inc. was incorporated in Delaware.

What is the SIC code for iBio, Inc.?

The Standard Industrial Classification (SIC) code for iBio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001420720-25-000005.txt : 20250113 0001420720-25-000005.hdr.sgml : 20250113 20250113075549 ACCESSION NUMBER: 0001420720-25-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250110 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250113 DATE AS OF CHANGE: 20250113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25524846 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250110x8k.htm 8-K iBio, Inc._January 10, 2025 0001420720 false 0001420720 2025-01-10 2025-01-10 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road ,  Suite 200 San Diego ,   California   92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO NYSE American ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ Item 1.01. Entry Into a Material Definitive Agreement. On January 10, 2025, iBio, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain of its officers and directors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in

View on Read The Filing